Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2011

Weber Britta, Sorensen Boe S, Knap Marianne Marquard, Madsen Hans Henrik, Nexo Ebba, Meldgaard Peter

Abstract excerpt

INTRODUCTION: Patients with non-small cell lung cancer with a sensitizing mutation in the epidermal growth factor receptor (EGFR) are likely to respond to treatment with an EGFR inhibitor. In some patients, residual tumor tissue can be visualized for several years without any signs of progression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22005472
DOI: 10.1097/JTO.0b013e31822e71f2

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22005472-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.PMID 22005472Read ↗

Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.Semantic proximity Read ↗

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.Semantic proximity Read ↗

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Semantic proximity Read ↗

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.Semantic proximity Read ↗

Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.Semantic proximity Read ↗

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.Semantic proximity Read ↗

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Response to Oral Erlotinib Monotherapy in a Patient With EGFR-Negative Status in Histology and Progressive Disease on Conventional Chemotherapy.Semantic proximity Read ↗

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.